公开(公告)号：US20230357142A9

公开(公告)日：2023-11-09

申请号：US17818889

申请日：2022-08-10

Applicant: Novartis AG

Inventor： Lech CISZEWSKI ,  Marilyn DE LA CRUZ ,  Piotr H. KARPINSKI ,  Michael MUTZ ,  Christian RIEGERT ,  Caspar VOGEL ,  Ricardo SCHNEEBERGER

IPC: C07D205/04 ,  A61K31/397 ,  C07C57/15

CPC classification number: C07D205/04 ,  A61K31/397 ,  C07C57/15

Abstract: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethy-l-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

公开(公告)号：US20220402870A1

公开(公告)日：2022-12-22

申请号：US17818889

申请日：2022-08-10

Applicant: Novartis AG

Inventor： Lech CISZEWSKI ,  Marilyn DE LA CRUZ ,  Piotr H. KARPINSKI ,  Michael MUTZ ,  Christian RIEGERT ,  Caspar VOGEL ,  Ricardo SCHNEEBERGER

IPC: C07D205/04 ,  A61K31/397 ,  C07C57/15

Abstract: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethy-l-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

公开(公告)号：US20210323915A1

公开(公告)日：2021-10-21

申请号：US17095052

申请日：2020-11-11

Applicant: Novartis AG

Inventor： Lech CISZEWSKI ,  Marilyn DE LA CRUZ ,  Piotr H. KARPINSKI ,  Michael MUTZ ,  Christian RIEGERT ,  Caspar VOGEL ,  Ricardo SCHNEEBERGER

IPC: C07D205/04 ,  A61K31/397 ,  C07C57/15

Abstract: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

公开(公告)号：US20240239743A1

公开(公告)日：2024-07-18

申请号：US18434514

申请日：2024-02-06

Applicant: Novartis AG

Inventor： Lech CISZEWSKI ,  Marilyn DE LA CRUZ ,  Piotr H. KARPINSKI ,  Michael MUTZ ,  Christian RIEGERT ,  Caspar VOGEL ,  Ricardo SCHNEEBERGER

IPC: C07D205/04 ,  A61K31/397 ,  C07C57/15

CPC classification number: C07D205/04 ,  A61K31/397 ,  C07C57/15

Abstract: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

公开(公告)号：US20180118678A1

公开(公告)日：2018-05-03

申请号：US15799235

申请日：2017-10-31

Applicant: Novartis AG

Inventor： Lech CISZEWSKI ,  Marilyn DE LA CRUZ ,  Piotr H. KARPINSKI ,  Michael MUTZ ,  Christian RIEGERT ,  Caspar VOGEL ,  Ricardo SCHNEEBERGER

IPC: C07D205/04 ,  C07C57/15 ,  A61K31/397

CPC classification number: C07D205/04 ,  A61K31/397 ,  C07C57/15

Abstract: This invention relates to a hemifumarate salt of 1-(4- 1-[(E)-cyclohexyl-3-tritluoromethy 1-benzy loxyimino ]-ethy 1)-2-ethy1-benzy l)-azetidine-3-carboxy lie acid (Compound) to pharmaceutics compositions comprising this salt, to processes for forming this salt and to its use in medical treatment, addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.